Insulin supply chain transparency needed to prevent price hikes
The Endocrine Society has reported that increasing costs of insulin means that people are often deciding to forgo necessary treatment...
List view / Grid view
The Endocrine Society has reported that increasing costs of insulin means that people are often deciding to forgo necessary treatment...
A study has found a novel mechanism underlying stable, durable blood sugar control...
First European filing acceptance of a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor in type-1 diabetes...
A drug-carrying microsphere within a cell-bearing microcapsule could be the key to transplanting insulin-secreting pig pancreas cells into human patients...
Researchers have devised a method for implanting islet cells into a patient that may control the management of type 1 diabetes...
The FDA has approved Admelog, a short-acting insulin indicated to improve control in blood sugar levels in diabetes...
A study has found that a majority of patients with Type 1 diabetes who were treated with dapagliflozin, a Type 2 diabetes medicine, had a significant decline in their blood sugar levels...
3 April 2017 | By Dr David Pugh, IDTechEx
The latest 2017 pipelines explores new emerging methods of glucose monitoring, analysing these technologies in the new report from IDTechEx Research...
5 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are pleased to announce that less than two years after forming a strategic alliance aimed at bringing new treatments to patients with diabetes, the companies will present 30 abstracts across three compounds and three classes of medicine at the 72nd American…